ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone - טבליות מצופות פילם - dydrogesterone 10 mg - dydrogesterone - dydrogesterone - cases where progesterone supplement is needed.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol; estradiol - טבליות מצופות פילם - dydrogesterone 10 mg; estradiol 1 mg; estradiol 1 mg - dydrogesterone and estrogen

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - טבליות מצופות פילם - dydrogesterone 2.5 mg; estradiol as hemihydrate 0.5 mg - dydrogesterone and estrogen

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - טבליות מצופות פילם - dydrogesterone 5 mg; estradiol as hemihydrate 1 mg - dydrogesterone and estrogen

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 150 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - pancreatic exocrine insufficiency.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 300 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - for the treatment of pancreatic exocrine insufficiency.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - acid casein 5.9 g / 100 ml; artificial vanilla 116 mg / 100 ml - liquid - combinations of electrolytes - oxepa is clinically shown to modulate the inflammatory response in critically ill, mechanically ventilated patients. it is appropriate for patients who have sepsis, ali (acute lung injury), or ards (acute respiratory distress syndrome).

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n